Hexakaprone Treatment for Post-Partum Hemorrhage Prophylactic
Status:
Unknown status
Trial end date:
2017-01-01
Target enrollment:
Participant gender:
Summary
Post-Partum Hemorrhage (PPH) is a common obstetrical complication. It may occur after both
vaginal and cesarean delivery with a reported prevalence of 4-6% of deliveries [1].
Prophylactic treatment with oxytocin after fetus extraction is a common practice.
[1,2]Transexamic acid - Hexakapron is a potent antifibrinolytic, it prevents lysine adhesion
to plasminogen molecules by blocking its binding site. It can lower fibrinolysis rate and by
that reduce bleeding [9]. Systematic treatment of anti-fibrinolytic drugs is in surgical
practice after procedures such as coronary artery bypass graft, orthopedic surgeries and
liver transplantation [10-13]. Hexakapron is an FDA approved drug, it is defined as a class B
drug for pregnancy and lactation [12], it is already being used in a non-routine fashion in
the delivery room during PPH.In obstetrics Hexakapron given before vaginal or cesarean
delivery has been presumed to decrease blood loss and PPH. 2 studies that included 453 woman
reported decrease in PPH (RR 0.51, 95% CI 0.36 to 0.72) [13-15]. However specific protocols
for prophylactic treatment with Hexakapron as available with oxytocin are lacking, and
further research is necessary to determine such guidelines [16].